VNDA

Vanda Pharmaceuticals (VNDA) is the lead sponsor of 18 active clinical trials listed on ClinicalTrials.gov^[5], including 10 Phase 3^[1], 4 Phase 2^[2], 2 Phase 1^[3], 1 Phase 4^[4].

Trial NCT06138613^[6] evaluates Tradipitant in Motion Sickness with a target enrollment of 705 participants. Trial NCT06701396^[7] evaluates Tasimelteon in Sleep Wake Disorders with a target enrollment of 60 participants. Trial NCT04326426^[8] evaluates Tradipitant in Coronavirus Infection with a target enrollment of 300 participants.

No Form 4 insider filings for VNDA were recorded at the SEC in the past 30 days^[9].